Strides Pharma Targets FY28 $375m–$400m U.S. Revenue

Strides Pharma Science Limited — Q4 & FY26 Earnings Call (FY ended Mar 31, 2026)

1. Overall Tone of Management: Optimistic

• Management repeatedly highlights “sustained improvement” and “structural transformation” with “highest ever EBITDA” and “operating PAT… crossing INR500 crores for the first time.”
• Forward-looking language is confident on margin targets and growth engines (“we remain confident,” “expect the benefits… starting in the second half of FY’27,” “should be able to get to that growth trajectory very soon”).
• However, they acknowledge specific headwinds (flu season miss, logistics/air freight escalation, access market donor funding challenges), but frame them as temporary and manageable.

2. Key Themes from Management Commentary

• Geographical diversification is accelerating
• Ex-U.S. mix rising to 46% of FY26 revenue (from ~41% in FY24); ~50% in Q4.
• Ex-U.S. growth described as delivering “faster than… initially anticipated.”
• Profitability transformation with margin expansion
• EBITDA margin expanded ~400 bps to ~19% in FY26.
• “Operating leverage is clearly visible” with operational PAT up 18x over 3 years.
• Gross margin target maintained at 58%–60%; aspiration to EBITDA >20%.
• Cash generation + deleveraging
• Operating cash flow INR703 crores; 76% EBITDA to operating cash conversion.
• Net debt/EBITDA improved to 1.55x (from 1.9x), despite currency headwind.
• U.S. softness attributed to specific, non-structural factors
• FY26 revenue growth 6.4% YoY, impacted by:
  • Flu season “did not materialize as expected” in H2 (U.S. Q4 seasonality weakened).
  • Access markets donor funding challenges (tactical impact).
• Controlled substances described as a quota/past-history-driven ramp with allocations “lower than expected in FY’26.”
• Investment cycle for future growth
• Growth capex + intangibles: INR418 crores (tangible INR236cr; intangible INR182cr), including nasal spray capacity build and ERP upgrade (SAP HANA).
• R&D/IP spend: INR2,500 million (~$30m) over 24 months, benefits expected from H2 FY’27.
• Ex-U.S. growth framed as “predictable/resilient”
• ORM (other regulated markets) described as high entry barrier / stable pricing / strong partner relationships.
• Africa strategy shifting toward branded share to improve margin resilience.
• Sandoz product acquisition (Feb’26) expected to contribute from H2 FY’27, strengthening Africa presence.

3. Q&A Analysis

Theme A: U.S. performance weakness, flu season, and launch/phasing

• Core questions
• What happened in the U.S. (product discontinuations, launches not going through)?
• Why is growth expected to recover only in H2 FY’27 (Q1/Q2 weaker)?
• Management response
• U.S. miss largely due to:
  • Seasonal flu demand not materializing (H2).
  • Controlled substances require past history + quota; ramp takes time.
  • Portfolio launch discipline: they avoid losing profitability; launches continue from 2H onward through ~’28.
• They emphasize growth will exist in near term but “full potential… more in the H2 onwards” due to 18–24 months execution timelines.
• Notable / evasive elements
• Limited specificity on which launches were delayed vs not launched; answers repeatedly revert to “portfolio discipline” and “market opportunity.”
• When asked about competition source, they cite “peer players” and molecule-level competition, but avoid naming.

Theme B: Controlled substances ramp, quotas, and margin impact

• Core questions
• How does controlled substances work (quota eligibility, DEA process)?
• Will controlled substances change margin trajectory toward the 20% EBITDA goal?
• What is the revenue potential / quota allocation outlook?
• Management response
• Detailed process: quota application → past history requirement → DEA additional quota after demonstrated sales → API → production → sell → re-apply.
• They confirm they completed a full year and will request additional quota; avoid specific revenue potential (“chicken and egg story”).
• Margin: “profitability is… similar” and “don’t think… change dramatically.”
• Notable / evasive elements
• Revenue potential for controlled substances was not disclosed despite direct questions.
• They argue controlled substances are a new entrant with only ~1.5 years experience, implying margin/scale will improve later.

Theme C: U.S. target ($375m–$400m) credibility and whether it’s exit run-rate

• Core questions
• Is $375m–$400m a FY’28 target or exit run-rate?
• How achievable is it given current ~$70m run-rate?
• Management response
• Clarified: not an exit run rate; it’s a full-year FY’28 aspiration/target.
• They say $400m aspiration has been consistent for years; they want to “chase that” because drivers are in place.
• They frame it as a “basket” across U.S. and other regulated markets.
• Notable / evasive elements
• No explicit quarterly math or bridge from current run-rate to FY’28 target; relies on “8 quarters to make it happen.”

Theme D: Pipeline commercialization timelines (nasal sprays, patches/films, R&D spend)

• Core questions
• When will nasal sprays and other modalities become meaningful?
• How much R&D spend going forward?
• What portion of pipeline filings will commercialize in the next year?
• Management response
• Nasal sprays: filed/filing momentum; “beyond ’28” for bulk revenue; some earlier possible.
• Patches and thin films: file in 12–18 months, commercialization later; “’28 and beyond.”
• R&D spend: “upwards of $25m” / $20m–$25m for coming 2 years.
• Notable / evasive elements
• When asked about 505(b)(2) pipeline specifics, they denied having such products (“we don’t have at all”), which may indicate either prior confusion or a change in how pipeline is categorized.

Theme E: Access markets / donor funding headwinds

• Core questions
• Any positives for growth markets this year?
• Order book visibility on donor funding.
• Management response
• Donor funding has been “subdued” due to Global Fund/institutional reductions; allocations rolling over.
• Some countries adding to fill gaps, but “gap is very big to fill.”
• Notable / evasive elements
• No quantified order book or timing for normalization.

4. Guidance / Outlook

Explicit guidance (quantitative)

• EBITDA margin aspiration: “upwards of 20%”
• Gross margin range: “58% to 60%”
• U.S. aspiration (FY’28): “US$375 million to US$400 million”
• Clarified in Q&A: full-year FY’28 target, not exit run-rate
• R&D spend: “upwards of $25 million” (stated as $20m–$25m for coming 2 years)
• Capex / investment run-rate (qualitative with numbers):
• Next 2 years: “around INR300 crores” (tangible mostly ends to maintenance; intangibles for rights)
• Dividend: Board recommended INR5 per share

Implicit signals (qualitative)

• U.S. recovery phasing: “full potential… from H2 onwards” (H2 FY’27) though “there will definitely be a growth” earlier.
• Controlled substances: additional quota request is expected to drive growth, but timing is quota-dependent (“no specific time line” on quota outcome).
• Ex-U.S. growth durability: described as “structural,” with ORM and Africa branded shift supporting margin resilience.
• Cost environment: logistics/air freight volatility acknowledged; management will try to “pass on” costs and maintain gross margin band.

5. Standout Statements (direct / high-signal)

• Structural shift in mix: “Ex-U.S. contribution has increased… to 46% in FY26… and on a Q4 basis… close to 50%.”
• Profitability milestone: “Operating PAT… crossing the INR500 crores mark for the first time.”
• U.S. headwind explanation: “The flu season did not materialize as expected in the second half.”
• Controlled substances ramp constraint: “Like we need a past history… depends on quota…”
• Growth phasing: “full potential of the growth… start to see from H2 onwards.”
• Margin targets reiterated: “EBITDA margins upwards of 20% and gross margins in the 58% to 60% range.”
• Investment timing: “benefits… starting in the second half of FY’27.”
• Quota outcome timing uncertainty: “There’s no specific time line to this” (quota result).

6. Red Flags / Positive Signals

Red flags
– U.S. target reliance without bridge: $375m–$400m FY’28 reiterated, but no detailed phasing/bridge from current run-rate; controlled substances revenue potential remains undisclosed.
– Seasonality explanation may recur: flu season miss is cited as key driver; management admits demand uptick “we don’t know” if it returns next year.
– Access market uncertainty: donor funding challenges remain unresolved; “gap is very big to fill.”
– Pipeline specificity gaps: limited disclosure on which launches were delayed; some pipeline categorization confusion (e.g., 505(b)(2) denial).

Positive signals
– Consistent profitability/cash narrative: sustained EBITDA margin expansion and improved ROCE; deleveraging despite currency headwind.
– Ex-U.S. momentum appears real: mix shift and ORM/Africa scaling are supported with multiple quarters of trend language.
– Operational discipline: repeated emphasis on discontinuing low-return products and maintaining gross margin band.
– Capex tied to capabilities: nasal spray capacity build + ERP upgrade + global rights with stated benefit timing.

7. Historical Comparison & Consistency Analysis (vs prior 3 calls provided)

Only one prior transcript was provided in full (Q3 FY26, Jan 30, 2026). The “previous 3–4 calls” requirement can’t be fully satisfied with the data provided; analysis below compares current FY26 call vs Q3 FY26 call.

a. Change in Tone Over Time

• Current call vs Q3 FY26: More Optimistic
• Q3 FY26: strong but more “on track” language; U.S. medium-term outlook “remains unchanged,” with more emphasis on rebuilding profitability and waiting for quota/seasonality.
• FY26 call: management claims results are “now visible,” “strategy delivering results faster,” and highlights “highest ever EBITDA” and structural mix shift.
• What changed
• More confidence on Ex-U.S. structural transformation (mix now ~46% vs earlier “gap reducing”).
• More concrete FY26 milestones (EBITDA margin ~19%, operating PAT milestone, net debt/EBITDA improvement).
• Still hedges on U.S. timing via quota/seasonality, but overall confidence is higher.

b. Tracking Past Commitments vs Outcomes (from Q3 FY26 call)

1) U.S. medium-term outlook / FY’28 revenue aspiration
– Past statement (Q3 FY26): reiteration of revenue aspirations for FY’28 supported by dormant products, controlled substances normalization, and R&D investments (no change in medium-term outlook).
– What expected: growth trajectory toward FY’28 target (previously framed around $400m).
– What happened now: FY26 U.S. impacted by flu season miss; controlled substances allocations “lower than expected”; FY’28 target now stated as $375m–$400m (slightly lower floor).
– Flag: ⏳ Delayed / softened (not necessarily missed, but confidence depends on H2 FY’27 recovery and quota outcomes; floor reduced to $375m).

2) Controlled substances quota cycle completion
– Past statement (Q3 FY26): “one full year of control substances… finish… in the next 3 months” and “next year should be fairly better.”
– What expected: improved quota/allocations and growth momentum after completing the cycle.
– What happened now: they say controlled substances completed a full year, but allocations in FY’26 were lower than expected; additional quota needed and timing is uncertain.
– Flag: ⏳ Delayed (cycle completed, but growth impact still constrained by quota/allocations).

3) Margin band credibility (gross margin 58–60%)
– Past statement (Q3 FY26): gross margin expected “between 58% to 60%” and aim for higher end.
– What happened now: gross margin target reiterated; FY26 EBITDA margin expanded to ~19% and they claim gross margin discipline with convergence of U.S./Ex-U.S. margins.
– Flag: ✅ Delivered (at least directionally; they cite sustained gross margin band in multiple quarters).

c. Narrative Shifts

• U.S. narrative shifts from “seasonality + quota delay” to “seasonality + portfolio discipline + H2 FY’27 full potential.”
• Ex-U.S. narrative becomes more dominant: Q3 FY26 emphasized “gap reducing” and Ex-U.S. contribution ~47%; FY26 call now emphasizes structural shift with mix ~46% and “resilient earnings driver.”
• Access market donor funding headwind becomes more explicit in FY26 call (donor funding challenges impacting access markets; tactical nature).

d. Consistency & Credibility Signals

• Medium credibility (based on limited history provided)
• Strength: consistent emphasis on profitability discipline, margin band, and Ex-U.S. growth.
• Weakness: U.S. growth remains dependent on seasonality and quota outcomes with limited quantification; targets are reiterated but not bridged with measurable milestones.
• Controlled substances: repeated “quota/past history” explanation is consistent, but outcomes (allocations “lower than expected”) suggest execution/ramp timing risk persists.

e. Evolution of Key Themes

• Demand/macro: from “flu season delayed” (Q3) to “flu season did not materialize as expected in H2” (FY26) — still unresolved, but framed as non-structural.
• Margins: consistently improving; FY26 adds stronger conversion metrics (EBITDA→operational PAT conversion, ROCE improvement).
• Expansion: Ex-U.S. expansion moves from “early momentum/green shoots” to “structural transformation delivering faster results.”
• Regulatory/pipeline: nasal spray and patches/films timelines remain “’28 and beyond,” with filings expected in 12–18 months.

f. Additional Insights (cross-period)

• U.S. target floor reduction ($400m → $375m–$400m) is a subtle but important shift toward conservatism, even while management claims drivers are in place.
• Cash-to-cash cycle increase is attributed to inventory build for Ex-U.S. resilience; this is a trade-off that could mask underlying working-capital pressure if growth slows.